# Martin J. van den Bent

Source: https://onco.cc/people/martin-van-den-bent/  
OnCo record `martin-van-den-bent` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Led the EORTC glioma trials that established chemotherapy for anaplastic gliomas and the value of 1p/19q and IDH status.

## Summary

Martin van den Bent led EORTC 26951, which showed adjuvant PCV chemotherapy doubles survival in 1p/19q-codeleted anaplastic oligodendroglioma, and the CATNON trial establishing adjuvant temozolomide in non-codeleted anaplastic glioma. He chaired the EORTC Brain Tumour Group and led the EANO glioma guidelines. His work built the molecular framework for glioma classification and treatment.

## Fields

- Kind: Person
- Last checked: 2026-09-10
- Tags: glioma; eortc; chemotherapy
- Role: Professor of Neuro-Oncology, Erasmus MC Cancer Institute
- Specialisms: Glioma; Anaplastic glioma; Chemoradiotherapy; EORTC trials

## Sources

- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=van%20den%20Bent%20MJ%5BAuthor%5D%20glioma

## Connected records

- cancers: [Glioma & glioblastoma](https://onco.cc/cancers/glioblastoma/)
- institutions: [Erasmus MC Cancer Institute](https://onco.cc/institutions/erasmus-mc/)
- trials: [EORTC 26981 / NCIC CE.3 (Stupp trial)](https://onco.cc/trials/eortc-26981/)
- key papers: [Stupp 2005: temozolomide added to radiotherapy for newly diagnosed glioblastoma](https://onco.cc/key-papers/paper-stupp-temozolomide-nejm-2005/)

---
JSON: https://onco.cc/api/v1/entities/martin-van-den-bent.json